Palavra-chave: CML

ALLOGENEIC BONE MARROW 2022 SARS-COV-2 STEM CELL TRANSPLANTATION COMORBIDITIES BCR-ABL NILOTINIB FIRST LINE TERAPHY DASATINIB PERIPHERAL BLOOD STEM CELLS TRANSPLANTATION BCR-ABL MUTATIONS TFR PBSC CYTOGENETIC REMISSION BCR/ABL GENE BRAZIL NILOTINIBE BCR/ABL GENE SEPT5 THIRD-LINE TKI TREATMENT PEDIATRIC PATIENTS NON-MYELOABLATIVE LOW EDUCATION LEVEL EDI-PIO GENERIC IMATINIB WHO TYROSINE KINASE INHIBITORS ENACT CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA CARDIOVASCULAR IMATINIB TKI PREGNANCY MULTICENTER STUDY PATIENTS IN BRAZIL CARDIOVASCULAR RISK F359V CARDIOVASCULAR EVENTS CHILDREN AND ADOLESCENTS DISCONTINUATION TRIAL HOCT1 BONE MARROW TRANSPLANTATION PIOGLITAZONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CHRONIC MYELOID LEUKEMIA SURVIVAL HMGCLL1 BCR-ABL1 D-HPLC DASATINIBE